Literature DB >> 25546751

Intravenous immunoglobulin for Alzheimer's disease.

N Relkin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25546751      PMCID： PMC4285480          DOI： 10.1111/cei.12500

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  16 in total

1.  Autoantibodies to amyloid-beta and Alzheimer's disease.

Authors:  B T Hyman; C Smith; I Buldyrev; C Whelan; H Brown; M X Tang; R Mayeux
Journal:  Ann Neurol       Date:  2001-06       Impact factor: 10.422

Review 2.  Intravenous immunoglobulin: exploiting the potential of natural antibodies.

Authors:  Srini V Kaveri
Journal:  Autoimmun Rev       Date:  2012-02-12       Impact factor: 9.754

3.  Measurement of anti-beta amyloid antibodies in human blood.

Authors:  Paul Szabo; Diana M Mujalli; Matthew L Rotondi; Rajal Sharma; Alfred Weber; Hans-Peter Schwarz; Marc E Weksler; Norman Relkin
Journal:  J Neuroimmunol       Date:  2010-07-31       Impact factor: 3.478

4.  Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.

Authors:  Rachelle S Doody; Ronald G Thomas; Martin Farlow; Takeshi Iwatsubo; Bruno Vellas; Steven Joffe; Karl Kieburtz; Rema Raman; Xiaoying Sun; Paul S Aisen; Eric Siemers; Hong Liu-Seifert; Richard Mohs
Journal:  N Engl J Med       Date:  2014-01-23       Impact factor: 91.245

5.  11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

Authors:  Juha O Rinne; David J Brooks; Martin N Rossor; Nick C Fox; Roger Bullock; William E Klunk; Chester A Mathis; Kaj Blennow; Jerome Barakos; Aren A Okello; Sofia Rodriguez Martinez de Liano; Enchi Liu; Martin Koller; Keith M Gregg; Dale Schenk; Ronald Black; Michael Grundman
Journal:  Lancet Neurol       Date:  2010-02-26       Impact factor: 44.182

6.  18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.

Authors:  Norman R Relkin; Paul Szabo; Basia Adamiak; Tuna Burgut; Carmen Monthe; Richard W Lent; Steven Younkin; Linda Younkin; Richard Schiff; Marc E Weksler
Journal:  Neurobiol Aging       Date:  2008-02-21       Impact factor: 4.673

7.  Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial.

Authors:  Richard Dodel; Axel Rominger; Peter Bartenstein; Frederik Barkhof; Kaj Blennow; Stefan Förster; Yaroslav Winter; Jan-Philipp Bach; Julius Popp; Judith Alferink; Jens Wiltfang; Katharina Buerger; Markus Otto; Piero Antuono; Michael Jacoby; Ralph Richter; James Stevens; Isaac Melamed; Jerome Goldstein; Stefan Haag; Stefan Wietek; Martin Farlow; Frank Jessen
Journal:  Lancet Neurol       Date:  2013-01-31       Impact factor: 44.182

8.  Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Authors:  Stephen Salloway; Reisa Sperling; Nick C Fox; Kaj Blennow; William Klunk; Murray Raskind; Marwan Sabbagh; Lawrence S Honig; Anton P Porsteinsson; Steven Ferris; Marcel Reichert; Nzeera Ketter; Bijan Nejadnik; Volkmar Guenzler; Maja Miloslavsky; Daniel Wang; Yuan Lu; Julia Lull; Iulia Cristina Tudor; Enchi Liu; Michael Grundman; Eric Yuen; Ronald Black; H Robert Brashear
Journal:  N Engl J Med       Date:  2014-01-23       Impact factor: 91.245

9.  Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease.

Authors:  Lakshman Puli; Yuriy Pomeshchik; Katja Olas; Tarja Malm; Jari Koistinaho; Heikki Tanila
Journal:  J Neuroinflammation       Date:  2012-05-29       Impact factor: 8.322

Review 10.  Is there a causal link between inflammation and dementia?

Authors:  Ana-Maria Enciu; Bogdan O Popescu
Journal:  Biomed Res Int       Date:  2013-06-06       Impact factor: 3.411
View more
  11 in total

Review 1.  Pharmacotherapy of Alzheimer's disease: an overview of systematic reviews.

Authors:  Reza Majidazar; Erfan Rezazadeh-Gavgani; Saeed Sadigh-Eteghad; Amirreza Naseri
Journal:  Eur J Clin Pharmacol       Date:  2022-07-26       Impact factor: 3.064

2.  A phase 3 trial of IV immunoglobulin for Alzheimer disease.

Authors:  Norman R Relkin; Ronald G Thomas; Robert A Rissman; James B Brewer; Michael S Rafii; Christopher H van Dyck; Clifford R Jack; Mary Sano; David S Knopman; Rema Raman; Paul Szabo; David M Gelmont; Sandor Fritsch; Paul S Aisen
Journal:  Neurology       Date:  2017-04-05       Impact factor: 9.910

3.  Neuroprotective effects of intravenous immunoglobulin are mediated through inhibition of complement activation and apoptosis in a rat model of sepsis.

Authors:  Figen Esen; Gunseli Orhun; Perihan Ergin Ozcan; Evren Senturk; Melike Kucukerden; Murat Giris; Ugur Akcan; Canan Ugur Yilmaz; Nurcan Orhan; Nadir Arican; Mehmet Kaya; Sema Bilgic Gazioglu; Erdem Tuzun
Journal:  Intensive Care Med Exp       Date:  2017-01-05

4.  Effects of Acyclovir and IVIG on Behavioral Outcomes after HSV1 CNS Infection.

Authors:  Chandran Ramakrishna; Mari S Golub; Abby Chiang; Teresa Hong; Markus Kalkum; Edouard M Cantin
Journal:  Behav Neurol       Date:  2017-11-19       Impact factor: 3.342

5.  Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease.

Authors:  David Gelmont; Ronald G Thomas; Jonathan Britt; Jacqueline A Dyck-Jones; Jennifer Doralt; Sandor Fritsch; James B Brewer; Robert A Rissman; Paul Aisen
Journal:  Alzheimers Dement (N Y)       Date:  2016-06-21

6.  The antigen-binding fragment of human gamma immunoglobulin prevents amyloid β-peptide folding into β-sheet to form oligomers.

Authors:  Victòria Valls-Comamala; Biuse Guivernau; Jaume Bonet; Marta Puig; Alex Perálvarez-Marín; Ernest Palomer; Xavier Fernàndez-Busquets; Xavier Altafaj; Marta Tajes; Albert Puig-Pijoan; Rubén Vicente; Baldomero Oliva; Francisco J Muñoz
Journal:  Oncotarget       Date:  2017-06-20

7.  Importance of neonatal immunoglobulin transfer for hippocampal development and behaviour in the newborn pig.

Authors:  Kateryna Goncharova; Liudmyla Lozinska; Ester Arevalo Sureda; Jarosław Woliński; Björn Weström; Stefan Pierzynowski
Journal:  PLoS One       Date:  2017-06-28       Impact factor: 3.240

8.  Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease.

Authors:  Andrew Satlin; Jinping Wang; Veronika Logovinsky; Scott Berry; Chad Swanson; Shobha Dhadda; Donald A Berry
Journal:  Alzheimers Dement (N Y)       Date:  2016-02-04

9.  Effective anti-Alzheimer Aβ therapy involves depletion of specific Aβ oligomer subtypes.

Authors:  Elysse M Knight; Soong Ho Kim; Jessica C Kottwitz; Asa Hatami; Ricardo Albay; Akinobu Suzuki; Alex Lublin; Cristina M Alberini; William L Klein; Paul Szabo; Norman R Relkin; Michelle Ehrlich; Charles G Glabe; Sam Gandy; John W Steele
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-05-10

Review 10.  Herpes Simplex Virus Type 1 and Other Pathogens are Key Causative Factors in Sporadic Alzheimer's Disease.

Authors:  Steven A Harris; Elizabeth A Harris
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.